Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
View Patent ↗The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
1. An isolated mutant form of stromal cell derived factor-1 (SDF-1) peptide comprising the formula of X p -mSDF-1, wherein said mSDF-1 in said X p -mSDF-1 comprises the amino acid sequence of at least amino acids 1-8 of SDF-1 amino acid sequence consisting of SEQ ID NO:52 and which is optionally extended at the C terminus of amino acids 1-8 of SEQ ID NO: 52 by all or any portion of the remaining sequence of SEQ ID NO:52, shown as amino acids 9-68 of the full-length of SEQ ID NO: 52 and said amino acids 1-8 comprises a mutation at the fourth or the fourth and the fifth amino acids from the N terminus of said amino acids 1-8 of SEQ ID NO:52, and wherein:
a) X is serine;
b) p equals one; and
c) said mutant form comprising X p -mSDF-1 has chemoattractant activity for T cells, is inactivated by dipeptidyl peptidase IV (DPPIV) at a rate that is less than one-half of the rate at which native SDF-1 is inactivated, and is inactivated by MMP-2 at a rate that is less than one-half of the rate at which native SDF-1 is inactivated.
2. The isolated mutant form of SDF-1 peptide of claim 1 , wherein said X p -mSDF-1 peptide has a mutation of serine to valine at the fourth amino acid from the N terminus of said amino acids 1-8 of SEQ ID NO:52.
3. The isolated mutant form of SDF-1 peptide of claim 1 , wherein said X p -mSDF-1 peptide has a mutation of serine to valine at the fourth amino acid and leucine to proline at the fifth amino acid from the N terminus of said amino acids 1-8 of SEQ ID NO:52.
4. The isolated mutant form of SDF-1 peptide of claim 1 , wherein said mutation of the fifth amino acid from the N terminus of amino acids 1-8 of SEQ ID NO:52 is not a mutation to a tryptophan or a glutamic acid amino acid residue.
5. An isolated mutant form of stromal cell derived factor-1 (SDF-1) peptide comprising the formula of X p -mSDF-1, wherein said mSDF-1 in said X p -mSDF-1 comprises the amino acid sequence of at least amino acids 1-17 of SDF-1 amino acid sequence consisting of SEQ ID NO:52 and which is optionally extended at the C-terminus of amino acids 1-17 of SEQ ID NO: 52 by all or any portion of the remaining sequence of SEQ ID NO:52, shown as amino acids 18-68, and wherein said amino acids 1-17 comprise a mutation at the fourth or the fifth, or mutations at the fourth and the fifth amino acids from the N terminus of said amino acids 1-17 of SEQ ID NO:52, and wherein:
a) X is serine;
b) p equals one; and
c) said mutant form comprising X p -mSDF-1 has chemoattractant activity for T cells, is inactivated by DPPIV at a rate that is less than one-half of the rate at which native SDF-1 is inactivated, and is inactivated by MMP-2 at a rate that is less than one-half of the rate at which native SDF-1 is inactivated.
6. The isolated mutant form of SDF-1 peptide of claim 5 , wherein said X p -mSDF-1 peptide has a mutation of serine to valine at the fourth amino acid from the N terminus of said amino acids 1-17 of SEQ ID NO:52.
7. The isolated mutant form of SDF-1 peptide of claim 5 , wherein said X p -mSDF-1 peptide has a mutation of leucine to proline at the fifth amino acid from the N terminus of said amino acids 1-17 of SEQ ID NO:52.
8. The isolated mutant form of SDF-1 peptide of claim 5 , wherein said mutation of the fifth amino acid from the N terminus of amino acids 1-17 of SEQ ID NO:52 is not a mutation to a tryptophan or a glutamic acid amino acid residue.
9. An isolated mutant form of SDF-1 peptide comprising the formula of X p -mSDF-1, wherein said mSDF-1 in said X-mSDF-1 comprises the amino acid sequence of at least amino acids 1-8 of SDF-1 amino acid sequence consisting of SEQ ID NO:52 and which is optionally extended at the C-terminus of amino acids 1-8 of SEQ ID NO: 52 by all or any portion of the remaining sequence of SEQ ID NO:52, shown as amino acids 9-68 of the full-length of SEQ ID NO:52, and wherein said amino acids 1-8 of SEQ ID NO:52 comprise a mutation at the fourth or the fifth, or mutations at the fourth and the fifth amino acid acids from the N-terminus of said amino acids 1-8 of SEQ ID NO:52, and wherein:
a) X is serine;
b) p equals one; and
c) said mutant form comprising X p -mSDF-1 has chemoattractant activity for T cells, is inactivated by DPPIV at a rate that is less than one-half of the rate at which native SDF-1 is inactivated, and is inactivated by MMP-2 at a rate that is less than one-half of the rate at which native SDF-1 is inactivated.
10. The isolated mutant form of SDF-1 peptide of claim 9 , wherein said X p -mSDF-1 peptide has a mutation of serine to valine at the fourth amino acid from the N terminus of said amino acids 1-8 of SEQ ID NO:52.
11. The isolated mutant form of SDF-1 peptide of claim 9 , wherein said X p -mSDF-1 peptide has a mutation of leucine to proline at the fifth amino acid from the N terminus of said amino acids 1-8 of SEQ ID NO:52.
12. The isolated mutant form of SDF-1 peptide of claim 9 , wherein said mutation of the fifth amino acid from the N-terminus of said amino acids 1-8 of SEQ ID NO:52 peptide is not a mutation to a tryptophan or a glutamic acid amino acid residue.
13. The isolated mutant form of SDF-1 peptide of claim 1 , 5 , or 9 , wherein said X p -mSDF-1 peptide mutant form maintains chemoattractant activity for T cells of at least 10% that of native SDF-1 and is inactivated by MMP-2 at a rate that is less than one-fourth of the rate of inactivation of native SDF-1.
14. An isolated mutant form of stromal cell derived factor-1 (SDF-1) peptide comprising the formula of mSDF-1 or X p -mSDF-1, wherein said mSDF-1 or said mSDF-1 in said X p -mSDF-1 comprises the amino acid sequence of at least amino acids 1-8 of SDF-1 amino acid sequence consisting of SEQ ID NO:52 wherein said amino acids 1-8 of SEQ ID NO:52 comprise mutations of serine to valine at the fourth amino acid and leucine to proline at the fifth amino acid from the N terminus of said amino acids 1-8 of SEQ ID NO:52, and which is optionally extended at the C-terminus of amino acids 1-8 of SEQ ID NO: 52 by all or any portion of the remaining sequence of SEQ ID NO:52, shown as amino acids 9-68 of the full-length of SEQ ID NO: 52, and wherein:
a) X is a proteinogenic amino acid or a protease protective organic group;
b) p is any integer from 1 to 4;
c) said mutant form comprising mSDF-1 has chemoattractant activity for T cells and is inactivated by matrix metalloproteinase-2 (MMP-2) at a rate that is less than one-half of the rate at which native SDF-1 peptide is inactivated; and
d) said mutant form comprising X p -mSDF-1 has chemoattractant activity for T cells, is inactivated by dipeptidyl peptidase IV (DPPIV) at a rate that is less than one-half of the rate at which native SDF-1 is inactivated, and is inactivated by MMP-2 at a rate that is less than one-half of the rate at which native SDF-1 is inactivated.
15. The isolated mutant form of claim 14 comprising said mSDF-1 or said X p -mSDF-1 maintains chemoattractant activity for T cells of at least 10% that of native SDF-1 and is inactivated by MMP-2 at a rate that is less than one-fourth of the rate of inactivation of native SDF-1.